Why the study?
Does gemcitabine and docetaxel show activity as first-line treatment in patients with unresectable leiomyosarcoma?
Does gemcitabine and docetaxel show activity as first-line treatment in patients with unresectable leiomyosarcoma?
Gemcitabine and docetaxel show activity as first-line chemotherapy for locally advanced or metastatic leiomyosarcoma, warranting further comparative trials.
Answers are grounded in this paper and cite their sources.
May support first-line gemcitabine-docetaxel in unresectable leiomyosarcoma; leaves open randomized comparisons.
This study demonstrates gemcitabine and docetaxel to be active in locally advanced/metastatic leiomyosarcoma in the first line setting. Further investigation comparing with current standard therapies for leiomyosarcoma is warranted.
No takes yet. Share an insight, caveat, or question.
Seddon et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: